Novo Nordisk Files Lawsuit Against Eli Lilly Over GLP-1 Advertising Claims
Danish healthcare company Novo Nordisk has filed a federal lawsuit against U.S. drugmaker Eli Lilly, alleging deceptive advertising for its competing GLP-1 drugs Mounjaro and Zepbound. The legal action claims the ads have caused widespread confusion in the market and demands their removal across all platforms.
